Dermapharm Holding SE
DMPHFOTCHealthcare● Active
$59.00
+$19.44(+49.14%)
Market Cap$2.9B
P/E Ratio—
52W High$59
52W Low$39.56
Dermapharm Holding SE (DMPHF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DMPHF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.16B | $1.18B | $1.15B | $1.02B | $0.94B |
| Cost of Revenue | $0.77B | $0.41B | $0.45B | $0.36B | $0.32B |
| Gross Profit | $0.39B | $0.77B | $0.70B | $0.66B | $0.62B |
| Gross Margin %(computed) | 33.62% | 64.96% | 61.19% | 64.49% | 65.83% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.02B | $0.01B | $0.01B |
| G&A Expenses | $0.00B | $0.01B | $0.02B | $0.02B | $0.01B |
| Total Operating Expenses | $0.17B | $0.55B | $0.52B | $0.42B | $0.33B |
| Operating Income | $0.22B | $0.22B | $0.18B | $0.24B | $0.30B |
| Operating Margin %(computed) | 19.03% | 18.37% | 15.89% | 23.78% | 31.65% |
| Interest Income | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.05B | $0.06B | $0.05B | $0.01B | $0.01B |
| Income Before Tax | $0.18B | $0.17B | $0.11B | $0.22B | $0.29B |
| Income Tax Expense | $0.05B | $0.06B | $0.05B | $0.08B | $0.08B |
| Net Income | $0.13B | $0.11B | $0.06B | $0.13B | $0.21B |
| Net Margin %(computed) | 11.37% | 9.64% | 5.42% | 13.10% | 22.23% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.46 | $2.11 | $1.16 | $2.49 | $3.89 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| EBITDA | $0.31B | $0.32B | $0.26B | $0.32B | $0.36B |
| EBITDA Margin %(computed) | 26.98% | 27.18% | 22.83% | 31.57% | 37.86% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · EUR · B
Explore more Dermapharm Holding SE data
About Dermapharm Holding SE (DMPHF) Income Statement
Dermapharm Holding SE (DMPHF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, DMPHF reported revenue of $1.16B, gross profit of $0.39B (gross margin 33.62%), and net income of $0.13B — a net profit margin of 11.37%.
Frequently asked questions
DMPHF · 4 questionsDermapharm Holding SE (DMPHF) reported revenue of $1.16B for 2025, down 1.4% year-over-year.
DMPHF revenueDMPHF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08